CN109096339B - 一种三联吡啶钌配合物的制备及在逆转录酶抑制中的应用 - Google Patents
一种三联吡啶钌配合物的制备及在逆转录酶抑制中的应用 Download PDFInfo
- Publication number
- CN109096339B CN109096339B CN201810799974.9A CN201810799974A CN109096339B CN 109096339 B CN109096339 B CN 109096339B CN 201810799974 A CN201810799974 A CN 201810799974A CN 109096339 B CN109096339 B CN 109096339B
- Authority
- CN
- China
- Prior art keywords
- complex
- terpyridyl
- ruthenium
- hiv
- terpyridyl ruthenium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 239000012327 Ruthenium complex Substances 0.000 title claims description 9
- 102100034343 Integrase Human genes 0.000 title abstract description 7
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 title abstract description 7
- 230000005764 inhibitory process Effects 0.000 title abstract description 6
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims abstract description 11
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 7
- 150000001768 cations Chemical group 0.000 claims abstract description 5
- -1 nitrothiazole compound Chemical class 0.000 claims description 31
- 229950003476 aminothiazole Drugs 0.000 claims description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 18
- 239000003446 ligand Substances 0.000 claims description 18
- JFJNVIPVOCESGZ-UHFFFAOYSA-N 2,3-dipyridin-2-ylpyridine Chemical compound N1=CC=CC=C1C1=CC=CN=C1C1=CC=CC=N1 JFJNVIPVOCESGZ-UHFFFAOYSA-N 0.000 claims description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- 238000010992 reflux Methods 0.000 claims description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 11
- 230000002829 reductive effect Effects 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 10
- 150000001450 anions Chemical class 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 239000002243 precursor Substances 0.000 claims description 9
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 claims description 7
- 238000001816 cooling Methods 0.000 claims description 7
- AJKVQEKCUACUMD-UHFFFAOYSA-N 2-Acetylpyridine Chemical compound CC(=O)C1=CC=CC=N1 AJKVQEKCUACUMD-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- 229960005130 niridazole Drugs 0.000 claims description 6
- 239000008096 xylene Substances 0.000 claims description 6
- 238000004440 column chromatography Methods 0.000 claims description 5
- 239000012046 mixed solvent Substances 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 5
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 claims description 4
- ZBVSOJZWZUGUAY-UHFFFAOYSA-N 2-bromo-2-nitro-1-phenylethanone Chemical compound [O-][N+](=O)C(Br)C(=O)C1=CC=CC=C1 ZBVSOJZWZUGUAY-UHFFFAOYSA-N 0.000 claims description 4
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 4
- 239000013078 crystal Substances 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 238000010898 silica gel chromatography Methods 0.000 claims description 4
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- ARKIFHPFTHVKDT-UHFFFAOYSA-N 1-(3-nitrophenyl)ethanone Chemical compound CC(=O)C1=CC=CC([N+]([O-])=O)=C1 ARKIFHPFTHVKDT-UHFFFAOYSA-N 0.000 claims description 3
- SZIFAVKTNFCBPC-UHFFFAOYSA-N 2-chloroethanol Chemical compound OCCCl SZIFAVKTNFCBPC-UHFFFAOYSA-N 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 claims description 3
- IPCRBOOJBPETMF-UHFFFAOYSA-N N-acetylthiourea Chemical compound CC(=O)NC(N)=S IPCRBOOJBPETMF-UHFFFAOYSA-N 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 3
- 239000012279 sodium borohydride Substances 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 229910001914 chlorine tetroxide Inorganic materials 0.000 claims description 2
- 239000003480 eluent Substances 0.000 claims description 2
- AEDZKIACDBYJLQ-UHFFFAOYSA-N ethane-1,2-diol;hydrate Chemical compound O.OCCO AEDZKIACDBYJLQ-UHFFFAOYSA-N 0.000 claims description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Chemical compound [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 claims description 2
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims 2
- 229910052707 ruthenium Inorganic materials 0.000 claims 2
- 229910017053 inorganic salt Inorganic materials 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- YBCAZPLXEGKKFM-UHFFFAOYSA-K ruthenium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Ru+3] YBCAZPLXEGKKFM-UHFFFAOYSA-K 0.000 claims 1
- YAYGSLOSTXKUBW-UHFFFAOYSA-N ruthenium(2+) Chemical compound [Ru+2] YAYGSLOSTXKUBW-UHFFFAOYSA-N 0.000 abstract description 41
- 230000003595 spectral effect Effects 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 11
- 239000003814 drug Substances 0.000 abstract description 7
- 230000027455 binding Effects 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 6
- 238000010839 reverse transcription Methods 0.000 abstract description 5
- 241000700605 Viruses Species 0.000 abstract description 4
- 238000000034 method Methods 0.000 abstract description 4
- 239000003112 inhibitor Substances 0.000 abstract description 2
- 230000010076 replication Effects 0.000 abstract description 2
- 238000012827 research and development Methods 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract 1
- 230000035484 reaction time Effects 0.000 abstract 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 16
- 239000007787 solid Substances 0.000 description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 6
- 108091034057 RNA (poly(A)) Proteins 0.000 description 6
- 108020000999 Viral RNA Proteins 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 3
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 3
- 230000004570 RNA-binding Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 3
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000002976 reverse transcriptase assay Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 1
- 229940124321 AIDS medicine Drugs 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 229910021135 KPF6 Inorganic materials 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000980 acid dye Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- JGBUYEVOKHLFID-UHFFFAOYSA-N gelred Chemical compound [I-].[I-].C=1C(N)=CC=C(C2=CC=C(N)C=C2[N+]=2CCCCCC(=O)NCCCOCCOCCOCCCNC(=O)CCCCC[N+]=3C4=CC(N)=CC=C4C4=CC=C(N)C=C4C=3C=3C=CC=CC=3)C=1C=2C1=CC=CC=C1 JGBUYEVOKHLFID-UHFFFAOYSA-N 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- BIXNGBXQRRXPLM-UHFFFAOYSA-K ruthenium(3+);trichloride;hydrate Chemical compound O.Cl[Ru](Cl)Cl BIXNGBXQRRXPLM-UHFFFAOYSA-K 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- ILXAOQAXSHVHTM-UHFFFAOYSA-M sodium;2-amino-2-(hydroxymethyl)propane-1,3-diol;chloride Chemical group [Na+].[Cl-].OCC(N)(CO)CO ILXAOQAXSHVHTM-UHFFFAOYSA-M 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000005758 transcription activity Effects 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0046—Ruthenium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/447—Systems using electrophoresis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Virology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- AIDS & HIV (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Electrochemistry (AREA)
- Pyridine Compounds (AREA)
Abstract
本发明属于艾滋病毒抑制剂研发领域,公开了一种三联吡啶钌(II)配合物的制备方法及其在艾滋病毒逆转录酶抑制中的应用。本发明的三联吡啶钌(II)配合物的阳离子部分的结构如式Ⅰ所示。本发明优化了三联吡啶钌(II)配合物的制备工艺,原料成本低,反应时间短。所得到的配合物纯度高、收率高,具有良好的水溶性和优异的光谱性质。本发明的三联吡啶钌(II)配合物具有对艾滋病毒RNA上的TAR区域选择性结合的能力,并能够阻断逆转录酶对病毒RNA的逆转录过程,抑制病毒RNA的复制。该三联吡啶钌(II)配合物是一种具有高亲和力的艾滋病毒RNA选择性结合试剂和高活性的艾滋病毒逆转录酶抑制剂,是极具应用潜力的艾滋病毒药物。
Description
技术领域
本发明属于艾滋病毒逆转录酶抑制剂研发领域,尤其涉及一种三联吡啶钌配合物的制备方法及其在艾滋病毒逆转录酶抑制中的应用。
背景技术
艾滋病是人类历史上最具破坏力的流行病。自2015年起,艾滋病已成为我国传染病死亡第一位。目前世界上尚未有任何药物或疗法能治愈艾滋病。2015年12月,世界卫生组织WHO的最新报告指出,逆转录酶抑制剂是目前最有希望治愈艾滋病的药物。大量实验证明,抑制逆转录酶对病毒RNA的逆转录作用,就可以控制病毒的产生和扩散,起到对艾滋病的治疗和早期防治作用(Science,1992,256,1783-1790;Biochemistry,2011,50,5042-5057)。因此,HIV逆转录酶成为当前抗艾滋病毒药物设计的首要靶点(Curr. Top. Med. Chem.,2004,4,1045-1057)。
目前,作为药物在临床中应用的逆转录酶抑制剂主要分为两类,即“核苷类逆转录酶抑制剂”和“非核苷类逆转录酶抑制剂”。核苷类逆转录酶抑制剂为核苷类似物,与病毒RNA逆转录形成的病毒DNA竞争结合逆转录酶,使病毒的复制得到一定程度上的抑制。然而,核苷类逆转录酶抑制剂的长期给药会产生严重的毒副作用(如抑制骨髓生长等)和出现明显的抗药性现象,面临着被淘汰的命运。通过大量新化合物的大规模活性筛选,人们陆续发现了一些结构各异的小分子化合物表现出较好的逆转录酶抑制活性,称其为非核苷类的逆转录酶抑制剂。它们对“酶-底物”复合物的亲和力比对酶的亲和力高,通过与逆转录酶的相互作用可以引起酶的构型变化,从而使底物活性部位的亲和性降低。由于非核苷类逆转录酶抑制剂不会直接损坏底物结合区域的功能,因此细胞毒性较小,并且在极低浓度即可抑制逆转录酶病毒的活性(Chem. Soc. Rev.,2012,41,4657-4670)。
TAR和RRE是艾滋病病毒RNA上两个重要的功能区域,对病毒RNA的逆转录活性起着至关重要的作用(Mol. Cell Biol.,1988,8,2555-2561)。新霉素(neomycin)等药物就是通过与病毒RNA上的TAR区域结合,从而阻断RNA与逆转录酶的结合并干扰病毒RNA的复制的(J. Am. Chem. Soc.,2000,122,12035-12036)。然而,能够特异性识别病毒RNA的TAR区域的小分子化合物的报道极少。最近,一种氨基噻唑类化合物表现出了较好的TAR RNA选择性(Chem. Eur. J.,2014,20,2071-2079;Chem. Commun.,2010,46,6162-6164)。该类化合物可以排除DNA和tRNA的影响,选择性的结合TAR RNA的U-A碱基对部位,抑制HIV-1菌株的生长,而对正常细胞的生长没有明显的影响。然而,作为有机小分子化合物,其水溶性低,缺乏能够应用的光吸收、荧光等光谱性质。
本专利发明了一种具有良好水溶性和光谱性质的三联吡啶钌(II)配合物,并在其结构中引入对艾滋病毒RNA具有特异性识别作用的氨基噻唑基团,使其能够选择性结合艾滋病毒RNA,并显著抑制艾滋病毒逆转录酶的活性。该三联吡啶钌(II)配合物不仅作为水溶性良好的艾滋病毒抑制剂,还能对RNA进行光谱响应,是潜在的艾滋病毒药物和光谱检测试剂。
发明内容
本发明的目的在于针对当前尚未攻克的艾滋病药物研究,提供一种具有良好水溶性和光谱性质的三联吡啶钌(II)配合物,其能够选择性结合艾滋病毒RNA,并显著抑制艾滋病毒逆转录酶的活性。
本发明的第二个目的是提供所述三联吡啶钌(II)配合物的制备方法。
本发明的第三个目的是提供所述三联吡啶钌(II)配合物在选择性结合RNA中的应用。
本发明的第四个目的是提供所述三联吡啶钌(II)配合物在抑制艾滋病毒逆转录酶中的应用。
本发明的上述目的通过如下技术方案予以实现:
一种三联吡啶钌(II)配合物,由阳离子和阴离子组成,所述阳离子结构式如式I所示:
式Ⅰ
式Ⅰ中,-L-间隔基团分别为-CO-、-C6H4CO-、-CONHCH2CO-,对应三联吡啶钌(II)配合物RuTz1、RuTz2、RuTz3。
本发明所述三联吡啶钌(II)配合物并不限定阴离子的种类,本领域常规阴离子均能实现本发明目的,尤其是无机盐阴离子,如PF6 -,ClO4 -、Cl-等,作为一种最优选方案,本发明所述三联吡啶钌(II)配合物的阴离子为PF6 -。
上述三联吡啶钌(II)配合物的制备方法,包括以下步骤:
S1. 2-乙酰吡啶和N,N-二甲基甲酰胺二甲基缩醛在二甲苯中回流,减压蒸馏除去二甲苯,正戊烷重结晶。晶体在四氢呋喃溶剂中再与2-乙酰吡啶反应,蒸馏除去四氢呋喃,甲苯作为洗脱剂做柱层析。得到的三联吡啶tpy与RuCl3在2-氯乙醇中回流,冷却至室温,抽滤,乙醇洗涤,真空干燥即得到前体配合物[Ru(tpy)Cl3]。
S2. 间硝基苯乙酮在乙醚中和溴素反应得到溴代硝基苯乙酮,并进一步与乙酰硫脲在乙醇中回流,得到硝基噻唑化合物(Tz-NO2)。硝基噻唑化合物在异丙醇中,用钯碳和硼氢化钠还原,二氯甲烷柱层析,得到氨基噻唑化合物(Tz-NH2),如式II所示:
式II
S3. 氨基噻唑化合物Tz-NH2分别与羧基三联吡啶tpyCOOH和羧基苯基三联吡啶tpyphCOOH在缩合试剂DCC和溶剂DMF中回流。减压蒸馏DMF,得到固体用大量水洗,真空干燥,得到氨基噻唑取代的三联吡啶配体tpyL1和tpyL2,其结构如式III和式IV所示:
式III
式IV
S4. 氨基噻唑化合物Tz-NH2先与叔丁氧羰基保护的甘氨酸缩合,再在浓KOH溶液中回流脱掉叔丁氧羰基,进一步与羧基三联吡啶tpyCOOH缩合,得到氨基噻唑取代的三联吡啶配体tpyL3,其结构如式V所示。
式V
S5. 前体配合物[Ru(tpy)Cl3]与氨基噻唑取代的三联吡啶配体在含4-乙基吗啉的乙二醇甲醚与水的混合溶液中回流,冷却过滤,滤液中加入KPF6水溶液,产生红色沉淀,过滤,真空干燥。经硅胶柱层析,以乙腈与甲醇混合溶剂洗脱唯一红色组分,得到所述目标三联吡啶钌(II)配合物。
优选地,上述步骤所述加热回流反应的条件为在80~120℃下回流2~4小时。
优选地,所述乙腈与甲醇混合溶剂为体积比4:1~2:1。
优选地,所述KPF6水溶液为质量分数10 %。
本发明具有以下有益效果:
本发明提供了一种新型三联吡啶钌(II)配合物,可作为艾滋病毒RNA选择性结合试剂和艾滋病毒逆转录酶抑制剂。本发明合成的三联吡啶钌(II)配合物结构稳定,具有良好的光谱性质,表现出良好的艾滋病毒RNA选择性结合和艾滋病毒逆转录酶抑制能力,是新型的艾滋病毒逆转录酶抑制剂。
本发明合成的三联吡啶钌(II)配合物在艾滋病毒逆转录酶抑制剂中的应用,具有以下优势:(1)具有良好的水溶性和稳定性;(2)具有良好的光谱性质,能够对艾滋病毒RNA进行光谱响应;(3)与氨基噻唑有机类化合物相比,具有更强的艾滋病毒逆转录酶抑制能力。
附图说明
图1为本发明所制备的三联吡啶钌(II)配合物分子结构图;
图2为前体配合物[Ru(tpy)Cl3]的合成途径;
图3为氨基噻唑化合物Tz-NH2的合成途径;
图4为氨基噻唑取代的三联吡啶配体tpyL1及其配合物RuTz1的合成途径;
图5为氨基噻唑取代的三联吡啶配体tpyL2及其配合物RuTz2的合成途径;
图6为氨基噻唑取代的三联吡啶配体tpyL3及其配合物RuTz3的合成途径;
图7为三联吡啶钌(II)配合物的紫外可见光谱随DNA或poly(A) RNA浓度变化;
图8为三联吡啶钌(II)配合物从结合tat多肽的TAR RNA上置换tat的电泳图;
图9为酶标仪记录的三联吡啶钌(II)配合物抑制艾滋病毒逆转录酶的活性曲线。
具体实施方式
以下结合说明书附图和具体实施例来进一步说明本发明。实施例仅用以解释本发明,而不用于对本发明做任何形式的限定。除非特别说明,本发明采用的试剂、方法和设备为本技术领域常规试剂、方法和设备,所用试剂和材料均为市购。
实施例1 三联吡啶钌(II)配合物的制备
所合成的三联吡啶钌(II)配合物分子结构如图1所示。
1、前体配合物[Ru(tpy)Cl3]的制备:
前体配合物[Ru(tpy)Cl3]按照图2所示的途径合成。称取2-乙酰吡啶(12.1 g,0.1mol)于圆底烧瓶中,加入N,N-二甲基甲酰胺二甲基缩醛(24.0 g,0.2 mol)和500 mL二甲苯,回流4小时。减压蒸馏除去二甲苯,正戊烷重结晶得到黄色晶体。该晶体加入到叔丁醇钾(23.0 g,0.2 mol)和2-乙酰吡啶(12.1 g,0.1 mol)的500 mL无水四氢呋喃溶液中,反应液由亮黄色转变为粉黄色。搅拌4小时,加入乙酸铵(77.0 g,1 mol)和醋酸(250 mL),搅拌5分钟。蒸馏除去所有溶剂,得到棕色固体。将该固体加入500 mL水中搅拌,加入碳酸钠固体调节pH值到7.0。二氯甲烷萃取,收集有机相并用硫酸镁干燥1小时。过滤,减压蒸干有机相得到浅黄色油状物,用二甲苯溶解,闪式柱层析(中性氧化铝100-200目),减压蒸干得到白色固体3.5 g,即为三联吡啶tpy。将三联吡啶(3.5 g,15 mmol)于圆底烧瓶中,加入水合三氯化钌(4.0 g,15 mmol),500 mL 2-氯乙醇,回流4小时,冷却静置1小时。过滤所得沉淀,用乙醇充分洗涤,真空干燥,得到棕色固体(5.6 g)。
2、氨基噻唑化合物(Tz-NH2)的制备:
氨基噻唑化合物(Tz-NH2)按照图3所示的途径合成。取间硝基苯乙酮(1.98 g,12mmol)于圆底烧瓶,加入无水乙醚(13 mL),冰水浴,搅拌,加入三氯化铝(80 mg),滴加溴素(0.7 mL,12 mmol),室温搅拌1小时。加水50 mL,乙醚萃取,收集有机相,减压蒸干得到白色固体。取白色固体(2.90 g,12 mmol)于圆底烧瓶,加入乙酰硫脲(1.42 g,12 mmol),在60mL无水乙醇回流30分钟,冷至室温,过滤,乙醇洗涤,干燥,得黄色固体,即为硝基噻唑化合物(Tz-NO2)。取硝基噻唑化合物(3.15 g,12 mmol)于圆底烧瓶,加入100 mL异丙醇,催化量的钯(5% Pd/C)和1.5 g硼氢化钠,室温搅拌3小时。减压蒸干溶剂,二氯甲烷柱层析,得白色固体,即为氨基噻唑化合物(Tz-NH2)。产量2.50 g,三步反应总收率90%。
3、氨基噻唑取代的三联吡啶配体tpyL1及其配合物RuTz1的制备:
按照图4所示的途径合成。于干燥的烧瓶中分别加入tpyCOOH(0.55 g,2 mmol)、氨基噻唑化合物Tz-NH2(0.47 g,2 mmol)、二环己基碳二亚胺DCC(0.41 g,2 mmol)、N,N-二甲基甲酰胺30 mL,室温搅拌3小时。减压蒸去溶剂,水洗,真空干燥,得到白色固体,即配体tpyL1。产量0.94 g,产率95%。取前体配合物[Ru(tpy)Cl3](0.79 g,1.8 mmol)和配体tpyL1(0.94 g,1.9 mmol)于烧瓶中,加入乙二醇甲醚50 mL和 4-乙基吗啉0.5 mL,回流4小时。冷至室温,过滤,向滤液中加入加入饱和KPF6(815 mg,5 mmol),析出沉淀,抽滤以收集沉淀,用水和乙醚洗,之后真空干燥得到粗产品。经硅胶柱层析,以乙腈与甲醇混合溶剂(体积比4:1)洗脱唯一红色组分,得到所述目标三联吡啶钌(II)配合物RuTz1。产量1.48 g,产率74%。1H NMR(300 MHz,DMSO-d 6):δ 12.33(s, 1H),11.05(s,1H),9.55(s,2H),9.14(d,J =6.0 Hz,2H),8.98(d,J = 6.0 Hz,2H),8.87(d,J = 6.0 Hz,2H),8.60(t,1H),8.54(s,1H),8.07(m,4H),7.82(dd,2H),7.62(d,J = 3.0 Hz,1H), 7.58(d,J = 6.0,1H ),7.50(t,4H),7.35(dt,4H),2.21(s,3H)。ESI-FTMS[CH3CN,m/z]=413.5687(理论值413.5700,[M-2PF6]2+)。
4、氨基噻唑取代的三联吡啶配体tpyL2及其配合物RuTz2的制备:
按照图5所示的途径合成。制备步骤同配合物RuTz1的制备,不同点在于将其中的tpyCOOH替代为tpyphCOOH(0.71 g,2 mmol),其余步骤及操作不变。配体tpyL2产量1.08 g,产率95%。目标三联吡啶钌(II)配合物RuTz2。产量1.80 g,产率83%。1H NMR(300 MHz,DMSO-d 6):δ 12.32(s,1H),10.60(s,1H),9.58(s,2H),9.14(t,4H),8.86(d,2H,J = 6.0 Hz),8.64(d,2H,J = 6.0 Hz),8.57(t,1H),8.50(s,1H),8.39(d,2H,J = 6.0 Hz),8.07(m,4H),7.77(d,1H),7.71(d,1H),7.58(m,6H),7.49(m,2H),7.32(q,2H),2.20(s,3H)。ESI-FTMS[CH3CN,m/z] = 451.5840(理论值:451.5850,[M-2PF6]2+)。
5、氨基噻唑取代的三联吡啶配体tpyL3及其配合物RuTz3的制备:
按照图6所示的途径合成。取叔丁氧羰基甘氨酸(0.35 g,2 mmol)和氨基噻唑化合物Tz-NH2(0.47 g,2 mmol)、二环己基碳二亚胺DCC(0.41 g,2 mmol)、N,N-二甲基甲酰胺30mL,室温搅拌3小时。减压蒸去溶剂,得到白色固体。固体用20 mL二氯甲烷溶解,再加入三氟醋酸(1.03 g,9 mmol),搅拌1小时,减压蒸干溶剂,得到油状固体。加入N,N-二甲基甲酰胺30 mL溶解,加入tpyCOOH(0.55 g,2 mmol)、二环己基碳二亚胺DCC(0.41 g,2 mmol)、30mL,室温搅拌3小时。减压蒸去溶剂,水洗,真空干燥,得到白色固体,即配体tpyL3。产量0.99g,产率90%。取前体配合物[Ru(tpy)Cl3](0.79 g,1.7 mmol)和配体tpyL3(0.99 g,1.8mmol)于烧瓶中,加入乙二醇甲醚50 mL和 4-乙基吗啉0.5 mL,回流4小时。冷至室温,过滤,向滤液中加入加入饱和KPF6(815 mg,5 mmol),析出沉淀,抽滤以收集沉淀,用水和乙醚洗,之后真空干燥得到粗产品。经硅胶柱层析,以乙腈与甲醇混合溶剂(体积比2:1)洗脱唯一红色组分,得到所述目标三联吡啶钌(II)配合物RuTz3。产量1.43 g,产率72%。1H NMR(300MHz,DMSO-d 6):δ 12.28(s,1H),10.41(s,1H),9.62(t,1H),9.51(s,2H),9.13(d,J = 8.4Hz,2H),8.87(t,5H),8.59(t,1H),8.28(s,1H),8.06(m,5H),7.61(dd,2H),7.47(m,4H),7.29(dt,4H),4.41(d,J = 5.7 Hz,2H),2.17(s,3H)。ESI-FTMS[CH3CN,m/z] = 442.0800(理论值:442.0800,[M-2PF6]2+)。
实施例2 三联吡啶钌(II)配合物的与RNA作用的紫外可见光谱检测
溶液的配置均采用称量法。溶剂为二次蒸馏水,缓冲体系为Tris-NaCl,pH 7.0。三联吡啶钌(II)配合物的浓度为2×10-5 mol/L,poly(A) RNA和DNA浓度范围约为5×10-6~5×10-5 mol/L,向固定浓度的三联吡啶钌(II)配合物的溶液中逐渐增加DNA或poly(A) RNA的浓度,分别记录配合物本身和不同RNA浓度下的紫外可见光谱。如图7所示,随着DNA或poly(A) RNA浓度的增加,三联吡啶钌(II)配合物RuTz1的紫外可见光谱基本没有变化,而RuTz2和RuTz3的紫外可见光谱随着poly(A) RNA的加入变化明显,而随着DNA的加入基本不变。这个结果证明,配合物RuTz2和RuTz3能够在紫外可见光谱上,对单链的RNA结构和双链的DNA结构进行差异性的光谱响应,其与poly(A) RNA相互作用的光谱变化幅度显著强于其与DNA相互作用的光谱变化。
实施例3 三联吡啶钌(II)配合物的与艾滋病毒RNA的识别作用
采用凝胶电泳法测试三联吡啶钌(II)配合物与艾滋病毒RNA的TAR区域的识别作用。在0.2 mL的PCR管中,配置一系列10μL溶液,其中分别含有2×10-6 mol/L的TAR RNA,2×10-6 mol/L的tat多肽,以及0~5×10-5 mol/L的三联吡啶钌(II)配合物。将溶液在37℃温浴30分钟,加入2μL的RNA电泳上样缓冲液,在10%聚丙烯酰胺凝胶电泳(尿素变性),110 V电压进行电泳1小时。经Gelred 4S核酸染料染色15分钟,于凝胶成像仪拍照,分析电泳条带。如图8所示,艾滋病毒TAR RNA本身显示一条带。在tat多肽存在时,部分TAR RNA与tat多肽以氢键结合,使得电泳显示两条带,即未结合和结合tat多肽的TAR RNA。当向该体系加入浓度逐渐升高的三联吡啶钌(II)配合物时,结合了tat的TAR RNA显著减少,证明配合物与TARRNA结合。实验证明,RuTz2的TAR RNA结合能力最强,其次为RuTz3,而RuTz1的结合能力最弱。该实验结果与实施例2中的紫外可见光谱变化规律相同。
实施例4 三联吡啶钌(II)配合物的艾滋病毒逆转录酶抑制活性
采用商用的艾滋病毒逆转录酶活性测试试剂盒(Reverse Transcriptase Assay,colorimetric, Roche)进行测试。如图9所示,在酶标仪上利用含有不同浓度配合物时逆转录结果的吸光度(405 nm)值,拟合该配合物抑制艾滋病毒逆转录酶活性的IC50值。从图中可得出RuTz1、RuTz2、RuTz3抑制艾滋病毒逆转录酶的IC50值分别为1.60、0.12、0.78μM,抑制活性显著高于同类有机化合物,是极具开发价值的潜在艾滋病毒药物。
Claims (4)
2.权利要求1所述三联吡啶钌配合物阴离子为PF6 -的配合物制备方法,其特征在于,制备步骤如下:
S1.2-乙酰吡啶和N,N-二甲基甲酰胺二甲基缩醛在二甲苯中回流12小时,减压蒸馏除去二甲苯,正戊烷重结晶,晶体在四氢呋喃溶剂中再与2-乙酰吡啶反应,蒸馏除去四氢呋喃,甲苯作为洗脱剂做柱层析,得到的三联吡啶tpy与三氯化钌在2-氯乙醇中回流,冷却至室温,抽滤,乙醇洗涤,真空干燥即得到前体配合物[Ru(tpy)Cl3];
S2.间硝基苯乙酮在乙醚中和溴素反应得到溴代硝基苯乙酮,并进一步与乙酰硫脲在乙醇中回流,得到硝基噻唑化合物Tz-NO2,硝基噻唑化合物在异丙醇中,用钯碳和硼氢化钠还原,二氯甲烷柱层析,得到氨基噻唑化合物Tz-NH2,如式II所示;
S3.氨基噻唑化合物Tz-NH2分别与羧基三联吡啶tpyCOOH和羧基苯基三联吡啶tpyphCOOH缩合,得到两种氨基噻唑取代的三联吡啶配体tpyL1和tpyL2,其结构如式III和式IV所示;
S4.氨基噻唑化合物Tz-NH2先与叔丁氧羰基保护的甘氨酸缩合,再在浓KOH溶液中回流脱掉叔丁氧羰基,进一步与羧基三联吡啶tpyCOOH缩合,得到氨基噻唑取代的三联吡啶配体tpyL3,其结构如式V所示;
S5.前体配合物[Ru(tpy)Cl3]与氨基噻唑取代的三联吡啶配体在含4-乙基吗啉的乙二醇甲醚与水的混合溶液中回流,冷却过滤,滤液中加入KPF6水溶液,产生红色沉淀,过滤,真空干燥,经硅胶柱层析,以乙腈与甲醇混合溶剂洗脱唯一红色组分,得到权利要求1所述三联吡啶钌配合物,其阴离子为PF6 -。
3.权利要求1中所述的三联吡啶钌配合物在制备艾滋病毒RNA选择性识别试剂的应用。
4.权利要求1中所述的三联吡啶钌配合物在制备艾滋病毒逆转录酶抑制剂的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810799974.9A CN109096339B (zh) | 2018-07-20 | 2018-07-20 | 一种三联吡啶钌配合物的制备及在逆转录酶抑制中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810799974.9A CN109096339B (zh) | 2018-07-20 | 2018-07-20 | 一种三联吡啶钌配合物的制备及在逆转录酶抑制中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109096339A CN109096339A (zh) | 2018-12-28 |
CN109096339B true CN109096339B (zh) | 2020-10-02 |
Family
ID=64846771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810799974.9A Expired - Fee Related CN109096339B (zh) | 2018-07-20 | 2018-07-20 | 一种三联吡啶钌配合物的制备及在逆转录酶抑制中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109096339B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111100133B (zh) * | 2019-12-30 | 2020-12-01 | 云南大学 | 一种金属卟啉化合物及其制法和应用 |
CN113354573B (zh) * | 2021-06-30 | 2023-03-17 | 河南阿尔法医药科技有限公司 | 一种可规模化生产α,α,α-三联吡啶的方法 |
CN115612090B (zh) * | 2022-10-20 | 2023-08-04 | 中国科学院长春应用化学研究所 | 一种聚乙二醇化的三联吡啶钌、制备方法及作为电化学发光试剂的应用 |
CN117158430B (zh) * | 2023-11-02 | 2023-12-29 | 云南民族大学 | 一种α,β-联吡啶化合物的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101830828A (zh) * | 2010-03-23 | 2010-09-15 | 中山大学 | 一种Salen Zn(Ⅱ)配合物及其制备方法和应用 |
-
2018
- 2018-07-20 CN CN201810799974.9A patent/CN109096339B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101830828A (zh) * | 2010-03-23 | 2010-09-15 | 中山大学 | 一种Salen Zn(Ⅱ)配合物及其制备方法和应用 |
Non-Patent Citations (4)
Title |
---|
Biophysical studies of a ruthenium(II) polypyridyl complex binding to DNA and RNA prove that nucleic acid structure has significant effects on binding behaviors;Hong Xu等;《J Biol Inorg Chem》;20051231;第10卷;第529-538页 * |
Recognition of G-U mismatches by tris(4,7-diphenyl-1,10-phenanthroline) rhodium;Christine S. Chow等;《Biochemistry》;19920623;第31卷(第24期);第5423-5429页 * |
Rh(Phen)2 Phi3+ as a Shape-Selective Probe of Triple Helices;Ai Ching Lim等;《Biochemistry》;19981231;第37卷;第9138-9146页 * |
Synthesis and spectroscopic RNA binding studies of [Ru(phen)2MHPIP]2+;Hong Xu等;《Inorganic Chemistry Communications》;20031231;第6卷;第766-768页 * |
Also Published As
Publication number | Publication date |
---|---|
CN109096339A (zh) | 2018-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109096339B (zh) | 一种三联吡啶钌配合物的制备及在逆转录酶抑制中的应用 | |
CN105732723B (zh) | 一种钌(ⅱ)多吡啶配合物及其制备与应用 | |
CN113603708B (zh) | 一种具有大环骨架结构的cdk9抑制剂的制备及其应用 | |
CN113683557B (zh) | 一种茂基铱/铑二聚体的应用 | |
CN111690036A (zh) | 一种高效抗肿瘤活性多肽Tubulysin M的制备方法 | |
CN111647040B (zh) | 一种天然活性多肽Tubulysin U的制备方法 | |
CN114133390B (zh) | 一种去氢骆驼蓬碱衍生物及其制备方法和应用 | |
CN108570076A (zh) | 一种含炔基的钌配合物及其合成方法与应用 | |
CN107286220B (zh) | 1,2,4-三氮唑偶联的二氢杨梅素衍生物及其制备方法和应用 | |
Mallah et al. | Nucleophilic substitution approach towards 1, 3-dimethylbarbituric acid derivatives—new synthetic routes and crystal structures | |
CN101823990B (zh) | 氨基酸酯基二硫代甲酸酯类化合物及其制备方法和用途 | |
JP6473519B2 (ja) | 3−ヒドロキシピリジン化合物、その製造方法及び医薬品製造における使用 | |
CN111233851A (zh) | 东莨菪素苯磺酰基呋咱氮氧化物类衍生物及其制备方法与用途 | |
CN109232663B (zh) | 一种钌配合物的制备方法及其艾滋病毒逆转录酶抑制应用 | |
CN101531683B (zh) | 分子内带有吩噻嗪供电基团的联吡啶钌/锇ecl标记物 | |
JP2023159030A (ja) | コロナウイルス3clプロテアーゼを標的とするvhlリガンドに基づくprotac、およびその調製方法と応用 | |
CN113105459B (zh) | 一种三唑并嘧啶衍生物及其制备方法和应用 | |
CN112457365B (zh) | 一类靶向蛋白质水解通路的功能分子及其制备和应用 | |
CN111793070B (zh) | 一类具有荧光特性[1,2,4]-三氮唑并环类化合物及其制备方法和用途 | |
CN109824583B (zh) | 一种苯基草酰胺类hiv-1抑制剂及其制备方法和应用 | |
CN113845557A (zh) | 雷公藤红素吡啶丙烯酸类衍生物及其制备方法与医药用途 | |
CN110078706B (zh) | 一种伊马替尼衍生物及其制备方法和用途 | |
CN113461760A (zh) | 4-硫代脱氧胸苷衍生物及其抗乙肝病毒制药应用 | |
CN113121612A (zh) | 一类含氟铂配合物及其应用 | |
CN111100133B (zh) | 一种金属卟啉化合物及其制法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20201002 Termination date: 20210720 |
|
CF01 | Termination of patent right due to non-payment of annual fee |